Apellis Pharmaceuticals, Inc. Logo

Apellis Pharmaceuticals, Inc.

Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.

APLS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 FIFTH AVENUE, 2451 WALTHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apellis Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds. The company leads in the science of the complement cascade, pioneering targeted C3 therapies to treat a broad range of debilitating diseases driven by uncontrolled or excessive activation of this part of the immune system. Apellis aims to develop transformative treatments for serious conditions in areas such as ophthalmology, nephrology, and hematology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apellis Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apellis Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apellis Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea
016580
Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT

Talk to a Data Expert

Have a question? We'll get back to you promptly.